2019
CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES
Mohammadi H, Tolpin A, Figura N, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Vogelbaum M, Robinson T, Yu M. CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES. Neuro-Oncology 2019, 21: vi54-vi55. PMCID: PMC6847278, DOI: 10.1093/neuonc/noz175.218.Peer-Reviewed Original ResearchStereotactic radiotherapyMedian timeRenal cell carcinoma brain metastasesDistant brain failureStage IV RCCMedian overall survivalOptimal treatment sequenceCox regression modelStereotactic radiation therapyWarrants further investigationDistant brainEligible lesionsNivolumab administrationBrain metastasesConsecutive patientsOverall survivalClinical outcomesBrain failureKaplan-MeierRetrospective databaseHemorrhagic lesionsNivolumabRadiation therapyPatient basisPatients
2013
Longitudinal trends in costs for palliative radiation for metastatic prostate cancer.
Robinson T, Dinan M, Li Y, Lee R, Reed S. Longitudinal trends in costs for palliative radiation for metastatic prostate cancer. Journal Of Clinical Oncology 2013, 31: 6554-6554. DOI: 10.1200/jco.2013.31.15_suppl.6554.Peer-Reviewed Original ResearchPalliative radiation therapyMetastatic prostate cancerProstate cancerRadiation therapyBony metastasesInclusion criteriaOutpatient facilitiesMedicare paymentsDistant metastatic diseaseTime of diagnosisPalliative radiation treatmentSEER-Medicare dataTreatment claimsStudy inclusion criteriaProstate cancer metastasisHealth care costsTotal Medicare paymentsAverage Medicare paymentsHealth care expendituresCarrier claimsPalliative radiationMetastatic diseasePalliative treatmentMedian ageMedian time